Washington, D.C. 20549     OMB APPROVAL     Check this box if no longer subject instancian 1pp.   STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP instancian 1pp.     Filed pursuant to Section 16(a) of the Securities Exchange Act of 1940     Samaa daverage burden hous per resonse:     Samaa daverage burden hous per resonse:     Samaa Bastiano     (Last)   (Middle)     C/OVERTEX PHARMACEUTICALS INC/ (Last)   S. Relationship of Reporting Person(s) to Issuer (Check all applicable)     Director   10% Owner Colspan="2">Other Celspan="2">(Director   10% Owner Colspan="2">Other Celspan="2">(Check all applicable)     Super Network Celspan="2">Colspan="2">Colspan="2">Colspan="2">Other Celspan="2">(Check all applicable)     Other Celspan="2">Celspan="2">(Middle)   Colspan="2">Other Celspan="2">(Check applicable)     (Check applicable)   Other Celspan="2">(Check applicable)     (Check applicable)   Other Celspan="2">(Check Applicable)     (Check Applicable)   Colspan="2">(Check Applicable)     (Check Applicable)   Check Applicable)   Check Applicable) <th <="" colspan="2" th=""><th>SEC For</th><th>m 4 FORM</th><th><b>4</b> U</th><th>INI</th><th>TED STAT</th><th>ΓES</th><th>SEC</th><th>URIT</th><th>IES</th><th></th><th>) EXCH</th><th>ANGE</th><th>E CON</th><th>/MIS</th><th>SION</th><th>J</th><th></th><th></th></th>	<th>SEC For</th> <th>m 4 FORM</th> <th><b>4</b> U</th> <th>INI</th> <th>TED STAT</th> <th>ΓES</th> <th>SEC</th> <th>URIT</th> <th>IES</th> <th></th> <th>) EXCH</th> <th>ANGE</th> <th>E CON</th> <th>/MIS</th> <th>SION</th> <th>J</th> <th></th> <th></th>		SEC For	m 4 FORM	<b>4</b> U	INI	TED STAT	ΓES	SEC	URIT	IES		) EXCH	ANGE	E CON	/MIS	SION	J		
□ bit be to a finite or another studed instruction 1(b).   STATE LEVEN FOR CHANGES IN BENCHCAL OWNERSTIP Instruction 1(b).   Estimated average burden hours per response.     1. Name and Address of Reporting Person' Samma Bastiano   2. Issuer Name and Ticker or Trading Symbol VERTEX PHARMACEUTICALS INC./ (Last) (First) (Middle)   5. Relationship of Reporting Person(s) to Issuer Check all applicable)     2. USUER Name and Ticker or Trading Symbol VERTEX PHARMACEUTICALS INCORPORATED   2. Issuer Name and Ticker or Trading Symbol VERTEX PHARMACEUTICALS INCORPORATED   5. Relationship of Reporting Person(s) to Issuer Check all applicable)     50 NORTHERN AVENUE   3. Date of Earliest Transaction (Month/Day/Year)   6. Individual or Joint/Group Filing (Check Applic Line)     (Street) BOSTON   MA   02210   4. If Amendment, Date of Original Filed (Month/Day/Year)   6. Individual or Joint/Group Filing (Check Applic Line)     (City)   (State)   (Zip)   7. Name Month/Day/Year)   3. Ascurites Acquired, Disposed of, or Beneficially Owned     1. Title of Security (Instr. 3)   2. Transaction Month/Day/Year)   8. A Deemed Execution Date (Month/Day/Year)   3. Ascurites Acquired, Disposed of, or Beneficially Owned (Line)   5. Amount of Beneficially Owned Following (Instr. 4)   5. Amount of Beneficially Owned Following (Instr. 4)   5. Amount of Beneficially Owned Following (Instr. 4)   5. Anount of Beneficially Owned Following (Instr. 4)   5. Anount of Beneficially Owned Following (Instr. 4)   5. Amount of																		DVAL		
And abd regioning in closing in clo	to Sec obligat	tion 16. Form 4 tions may conti	or Form 5	Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934									Estima			ated average bur	3235-0287 den 0.5			
(Last)   (First)   (Middle)   (						VE	VERTEX PHARMACEUTICALS INC /							(Check all applicable) Director 10% Owner   X Officer (give title below) Other (specify below)						
4. If Amendment, Date of Original Filed (Month/Day/Year)   6. Individual or Joint/Group Filing (Check Applic Line)     (Street) BOSTON   MA   02210	C/O VERTEX PHARMACEUTICALS																			
(Street) DOSTON   MA   02210   X   Form filed by One Reporting Person Form filed by More than One Reporting Person     City (City) (State) (Zip)     Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Date (Month/Day/Year)   3. (A Deemed (Month/Day/Year)   3. (A Month   Count of (D)   S. Amount of (D) </td <td colspan="6">50 NORTHERN AVENUE</td> <td colspan="7">4. If Amendment, Date of Original Filed (Month/Day/Year)</td> <td colspan="5">6. Individual or Joint/Group Filing (Check Applicable Line)</td>	50 NORTHERN AVENUE						4. If Amendment, Date of Original Filed (Month/Day/Year)							6. Individual or Joint/Group Filing (Check Applicable Line)						
Table 1 - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned     1. Title of Security (Instr. 3)   2. Transaction Date (Month/Day/Year)   2. Transaction Date (Month/Day/Year)   2. Transaction Date (Month/Day/Year)   3. Transaction Code (Instr. 8)   4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)   5. Amount of Securities Beneficially Owned Following (Instr. 4)   5. Amount of Beneficially Owned Following (Instr. 4)   5. Amount of Beneficially Owned Following (Instr. 4)   6. Ownership Or Disposed Of (D) (Instr. 3, 4 and 5)   5. Amount of Beneficially Owned Following (Instr. 4)   6. Ownership Or Disposed Of (D) (Instr. 3, 4 and 5)     Common Stock   05/04/2022   S <sup>(1)</sup> 36   D   \$275.09 <sup>(2)(3)</sup> 41,660   D     Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)     1. Title of Derivative (Instr. 3)   3. Transaction Date Price of Derivative Security (Instr. 3)   3. Transaction Date (Month/Day/Year)   3. Deemed Execution Date, (A) or Derivative Securities (A) or Derivative Securities (A) or Derivative Securities (Month/Day/Year)   3. Number of (D) or Derivative Securities (A) or Derivative Securities (A) or Derivative Securities (A) or Derivative Securities (A) or Derivative Securities (A) or Derivative Securities (A) or Derivative Securities (A) or Derivative Securities (A) or Derivative Securities (A) or Derivative Securities (B) Owned (A) or Derivative Securities (B) Owned (A) or Derivative Securities (B) Owned (A) or Derivative Secur														X Form filed by One Reporting Person Form filed by More than One Reporting						
1. Title of Security (Instr. 3)   2. Transaction Date (Month/Day/Year)   2. Transaction Date (Month/Day/Year)   2. Transaction Date (Month/Day/Year)   3. Transaction (Month/Day/Year)   3. Transaction (Month/Day/Year)   3. Transaction (Month/Day/Year)   3. Transaction (Month/Day/Year)   3. Transaction (Month/Day/Year)   5. Amount of Securities (Instr. 3, 4 and 5)   5. Amount of Securities Beneficially (Instr. 3, 4 and 5)   6. Ownership Securities Beneficially (Instr. 4)   7. Na Securities Beneficially (Instr. 3, 4 and 5)     Common Stock   05/04/2022   s(1)   36   D   \$275.09(2)(3)   41,660   D     Title of Derivative (Instr. 3)   3. Transaction Date Price of Derivative (Instr. 3)   3. Transaction Date Price of Derivative Security (Instr. 3)   3. Transaction Date Price of Derivative Security (Instr. 3)   3. Deemed Execution Date, if any (Month/Day/Year)   4. Transaction Date (Instr. 8)   5. Number of Code (Instr. 8)   6. Date Exercisable and Expiration Date (Month/Day/Year)   7. Title and Anount of Securities Derivative Securities (Month/Day/Year)   8. Price of Derivative Securities (Month/Day/Year)   9. Number of Or Indirect (I) (Instr. 4)   10. Ownership Price	(City) (State) (Zip)																			
$\frac{1}{10000000000000000000000000000000000$			Table	el-	Non-Deriva	ative	Secur	ities A	Acqui	red, I	Disposed	of, or	Benefi	cially	Owne	ed				
Common Stock   05/04/2022   s(1)   Amount   (A) or (D)   Price   Transaction(s) (Instr. 3 and 4)   Transaction(s)     Common Stock   05/04/2022   s(1)   36   D   \$275.09^{(2)(3)}   41,660   D     Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)     1. Title of Derivative Security   3. Transaction or Exercise Price of Derivative Security   3. Transaction Date (Month/Day/Year)   3. Deemed Execution Date, (Month/Day/Year)   5. Number of Executies (Month/Day/Year)   6. Date Exercisable and of Derivative Securities Acquired (A) or Disposed of (D)   7. Title and Amount of Security (Instr. 5)   8. Price of Derivative Security (Instr. 5)   9. Number of derivative Security (Instr. 4)   10. Ownership Form: Disposed of (D)	Date				ear) E	Execution Date, ar) if any							d 5) Securitie Beneficia Owned F		ies ially Following	Form: Direct (D) or Indirect (I)	7. Nature of Indirect Beneficial Ownership			
1. Title of Derivative (Instr. 3)   2. Conversion Security   3. Transaction Date (Month/Day/Year)   3. Transaction Date (Month/Day/Year)   3. Transaction Date (Month/Day/Year)   3. Transaction Transaction Derivative Securities   3. Transaction Derivative Securities   3. Transaction Date (Month/Day/Year)   3. Transaction (Month/Day/Year)   3. Deemed Execution Date, (Month/Day/Year)   5. Number of Derivative Securities   6. Date Exercisable and Expiration Date (Month/Day/Year)   7. Title and Acquired (A) or Disposed of (D)   8. Price of Derivative Securities   9. Number of derivative Securities   10. Ownership Form: Direct (D) Ownership Securities									Code	v	Amount		Price		Transad	ction(s)	(instr. 4)	(1150.4)		
(e.g., puts, calls, warrants, options, convertible securities)	Common Stock 05/04/2022					2			<b>S</b> <sup>(1)</sup>		36	D	\$275.0	<b>9</b> <sup>(2)(3)</sup>	41	,660	D			
Derivative Security (Instr. 3) Detervative Security Derivative Security (Instr. 3) Date (Month/Day/Year) Date (Month/Day/Year) Date (Month/Day/Year) Date (Month/Day/Year) Derivative Securities Security Securities Security Securities Security Securities Security Securities Security Securities Securiti			Ta	able											wned	l				
(Instr. 3, 4 and 5) Amount	Derivative Security	Conversion or Exercise Price of Derivative	Date	Ex if a	ecution Date,	Trans Code		of Derivati Securiti Acquire (A) or Dispose of (D) (Instr. 3	ive (M ies ed ed	piratio	n Date	Ame Sec Und Der Sec	ount of urities erlying vative urity (Inst ad 4)	Deriv Secu (Inst	vative ırity r. 5)	derivative Securities Beneficially Owned Following Reported	Ownershi Form: Direct (D) or Indirec (I) (Instr. 4	Beneficia Ownersh t (Instr. 4)		

Explanation of Responses:

1. Transaction made pursuant to Dr. Sanna's company approved trading plan under Rule 10b5-1.

2. Dr. Sanna undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price.

(A) (D)

Date Exercisable Expiration Date

3. Open market sales reported on this line occurred at a weighted average price of \$275.09 (range \$275.00 to \$275.11).

## **Remarks:**

/s/ Sabrina Yohai, Attorney-in-Fact 05/06/2022

\*\* Signature of Reporting Person Date

or Number

of Shares

Title

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

 $^{\ast}$  If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Code V

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.